Biosynex S.A.

22, boulevard Sebastien Brant, 67400 Illkirch-Graffenstaden
France
Telephone +33 3 88788081
Fax +33 3 88779068
export@biosynex.com
http://www.biosynex.com

Product Categories

Product categories

03 Diagnostic Tests
03.02 Immunochemistry testing, immunology testing
03.02.02 Diagnostic rapid tests

Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests
Streptococcus A (CE)
Streptococcus pyogenes are non-motile gram-positive cocci, which can colonize human organs and
cause serious infections. Beta-haemolytic Group A Streptococci (Streptococcus pyogenes) are the
main cause for infections of the upper respiratory tracts, especially angina. An early diagnosis and
treatment of Group A Streptococcal angina reduces symptoms severity and further complications,
such as rheumatic fever and glomerulonephritis.

Product category: Diagnostic rapid tests
Rapid detection test Legionella & Streptococcus pneumoniae (CE)
Legionnaires’ disease is a serious form of pneumonia, whose mortality reaches 10-15% in healthy people. The disease
can cause flu symptoms followed by a dry cough, frequently progressing to pneumonia. The incubation period
normally lasts from 2 to 10 days, with the disease is typically occurring after 3 to 6 days. Legionellosis can occur as an
epidemic of two or more cases, following a single-source limited exposure in time and space, in the form of a series of
independent cases serial in an area where the disease has become very endemic ; or as sporadic cases with no obvious
geopgraphic or temporal grouping.
BIOSYNEX® Legionella is a single-use immunochromatographic rapid test, for serogroup 1 Legionella pneumophila
infection early diagnostics, by specific antigen detection in urine.

Product category: Diagnostic rapid tests
Clostridum D & Toxin A/B (CE)
Clostridium diffcile is an anaerobic spore-forming bacterium which opportunistically dominates in the gastrointestinal
tract when other flora are impacted by the use of antibiotics. C. diffcile has become one of the most serious nosocomial
pathogens impacting hospitals, nursing homes and other medical institutions. C. diffcile causes antibiotic associated
diarrhea and pseudo-membranous colitis (PC), a severe inflammation of the colon which can be life threatening, especially
among the elderly. The detection of C. diffcile enzyme and toxins is essential for optimal diagnosis :
1- Initial stool screening with a GDH immunoassay test (sensitive for C. diffcile detection) : IMMUNOQUICK® C. diffcile GDH.
2- If GDH positive, a second specific test is performed to determine the presence of enterotoxin A & cytotoxin B with
IMMUNOQUICK® Tox A/B.

Product category: Diagnostic rapid tests
Rapid immunity test against Tetanus (CE)
The tetanus toxin of Clostridium tetani bacteria binds to the cell membranes of the peripheral nerves and inhibits the
delivery of neurotransmitters. Immunization is the best way to prevent Clostridium tetani infections in children and
adults. It is sometimes desirable to know the level of anti-tetanus toxoid antibodies in a subject, in order to evaluate
his/her immunitary status and determine the need for complementary vaccination.
TETANOTOP® test is a rapid immunochromatographic test for the detection of anti-tetanus toxoid antibodies in
human serum, plasma or whole blood, to evaluate anti-tetanus immunity.

Product category: Diagnostic rapid tests
Malaria infection (CE)
The PALUTOP®+4 OPTIMA test is a rapid immunochromatographic for the qualitative detection of P. falciparum specifc
Pf HRP-2 antigen (histidine rich protein-2), P. vivax specifc pLDH & pLDH common to all Plasmodium species. The test
can be used for the specifc detection of P. falciparum & P. vivax, for the differential diagnosis of P. malariae & P. ovale,
and for monitoring antimalaric treatments.
Each batch of PALUTOP®+4 OPTIMA is tested on patient samples at the Institute of Parasitology and Tropical Pathology
of Strasbourg.

Product category: Diagnostic rapid tests
Plasmodium Falciparum detection test (CE)
Malaria is a serious, sometimes fatal, parasitic disease characterized by fever, chills and anemia, and caused by a
parasite transmitted from one human to another by anophel mosquitoes. Five plasmodium species can infect humans:
Plasmodium falciparum, P. vivax, P. ovale, P. malariae and P. kwolesi. In humans, sporozoites migrate to the liver, where
they develop and release into blood another form, merozoites, which infects erythrocytes. Half of the worldwide
population is exposed to malaria risk : in 2015, 212 million cases were identifed, and the disease caused 429,000
deaths.
First Response® Malaria Ag. P. falciparum is a single use immunochromatographic qualitative test for the detection
of Histidin Rich Protein 2 (HRP2) antigen in blood, in order to allow the practician to apply the adaptated therapy.

Product category: Diagnostic rapid tests
TRIPLEX HIV, HBV, HCV
35 million people in Africa are infected with the HIV virus, 16 million of whom have access to treatment
and 2 million people are newly infected each year. In addition, in 2017, the World Health Organization
(WHO) reports that 325 million people are living with chronic hepatitis B virus (HBV) or hepatitis C
(HCV) infection. The report says that the majority (> 250 million) of these people do not have access to
screening and treatment that could save their lives. As a result, millions of people are confronted with the
risk of slow development towards chronic liver disease, cancer and death.

Product category: Diagnostic rapid tests
Influenza (A+B) & RSV (CE)
Influenza (commonly known as ‘flu’) is a highly contagious, acute viral infection of the respiratory tract. It is a communicable
disease easily transmitted through the coughing and sneezing of aerosolized droplets containing live virus. Influenza
outbreaks occur each year during the fall and winter months. Type A viruses are typically more prevalent than type B
viruses and are associated with most serious influenza epidemics, while type B infections are usually milder.
INFLUENZATOP® BSS is a rapid immunochromatographic test for for the qualitative detection of Influenza type A and
type B antigens in human nasal swab, throat swab or nasal aspirate samples.

ad: contact information

About Us

Company details
Biosynex develops, manufuactures, and markets medical devices for screening, diagnosis ans prevention in a constant quest for excellence. These simple, easy to use tests are used by health professionnals to facilitate the care of patients, and by the general public so that everyone can monitor their health. In this way we contribute to better PUBLIC HEALTH at all stages of life.

Located in Strasbourg (France), the BIOSYNEX Company was born in 2005 and is specialized in the design and distribution of rapid diagnostic tests (RDT). Today, BIOSYNEX is the leader of the RDT French market.

Fast and easy to use, these RDTs are commercialized in France and in some 60 countries through local distributors. By targeting the general public and health professionals, BIOSYNEX brings concrete and effective answers to public health issues at the heart of today’s preoccupations.

Self-tests
Self-tests are the general public version of RDTs and are available in pharmacies. These allow self-monitoring for multiple applications, such as: HIV, pregnancy diagnosis, ovulation period, male fertility, urinary tract infections, vaginal infections, etc.

Professional tests
RDTs may be used by health professionals (analytical laboratories, doctors) for diagnostic orientation. They allow an appropriate management of the patient both in consultation and in emergency. As an example, BIOSYNEX has been supplying around 50,000 liberal doctors with a strep test, Streptatest® for the last few years as part of the call for tenders launched by the National Health Insurance Fund for Employees (CNAMTS), thus improving significantly the screening for bacterial angina and limiting the overconsumption of antibiotics.

RDTs may also be used in the analytical laboratory for the realization of piecemeal tests.

BIOSYNEX also commercializes a panel of instruments and machines which can be used in POC, as well as other tests for analytical laboratories based on technologies for confirmation diagnosis such as immunoblotting or molecular biology.

ad: company

M-technologies Sarl
BIOMEDISYST SAS
BioparHom SAS
Biotechni SAS
Biowest SAS
Blispac SAS
BioparHom SAS
BIOMEDISYST SAS
M-technologies Sarl
LSO Medical SAS
Lille Eurasanté GIE

Biotechni SAS
Biowest SAS
Blispac SAS
BLUELINEA SA
BMB MEDICAL SAS